# Effect of Patient Management Based on Continuous Continuous Glucose Monitoring on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes and Moderate to Severe Coronary Artery Stenosis

Study · id `cardio:ct-nct06060483` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06060483](<https://clinicaltrials.gov/study/NCT06060483>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06060483

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 4000 participants.

## Technical summary

Registry record NCT06060483. Randomized; no masking; primary purpose prevention. Start 2024-01 (anticipated); primary completion 2025-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Not applicable
- Enrolled: 4000 participants (planned count; ClinicalTrials.gov record NCT06060483, source copy `cardio:ctgov-nct06060483-2023-09-29`, retrieved 2026-10-26)
- Planned start: 2024-01 (anticipated) (ClinicalTrials.gov record NCT06060483, source copy `cardio:ctgov-nct06060483-2023-09-29`, retrieved 2026-10-26)
- Primary completion: 2025-12 (anticipated) (ClinicalTrials.gov record NCT06060483, source copy `cardio:ctgov-nct06060483-2023-09-29`, retrieved 2026-10-26)
- Completion: 2026-01 (anticipated) (ClinicalTrials.gov record NCT06060483, source copy `cardio:ctgov-nct06060483-2023-09-29`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06060483, source copy `cardio:ctgov-nct06060483-2023-09-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06060483-2023-09-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Patient Management Based on Continuous Continuous Glucose Monitoring on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes and Moderate to Severe Coronary Artery Stenosis
- Condition: Diabetes Mellitus, Type 2
- Condition: Major Adverse Cardiac Events
- Intervention (Device): CGM
- Lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine (`cardio:org-second-affiliated-hospital-zhejiang-university-school-of-bfd3ac`)

## Provenance

Content hash: 55605f268b34e393cd3e7672768fbf0ec0cf029d0ab7d5c96f3fccce5c970dd1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
